AbbVie and Genmab disclosed that Epkinly (their anti‑CD47/PD‑1 program or other named asset in a late‑stage study) did not prolong overall survival in a Phase 3 trial for diffuse large B‑cell lymphoma (DLBCL). The randomized study enrolled patients who had received at least one prior therapy and failed to meet the primary endpoint of improved overall survival. The negative Phase 3 readout removes a late‑stage commercial pathway for the drug in DLBCL and will force reassessment of regulatory and development plans by both companies. AbbVie and Genmab said they will analyze the full dataset to understand subgroup effects and next steps.